SNDX Syndax Pharmaceuticals, Inc. Loading...

From INCY earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:00
Jul 28 ◎
Pablo CSO, Incyte Corporation INCY Q2 FY26 call
Syndax is running the Niktimbo IPF study; its data readout will be a key catalyst for a potential opt-in decision by Incyte.
SNDX
HIGH

About SNDX Analyst Coverage

Buzzberg tracks SNDX (Syndax Pharmaceuticals, Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Pablo.